Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:1474 (17 December), doi:10.1136/bmj.331.7530.1474-b
| The first 150 words of the full text of this article appear below. |
EDITORThe study by Hippisley-Cox et al into the safety of cyclo-oxygenase-2 (COX-2) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDS) is subject to more indication bias than they suggest.1
When the study began, five years ago, COX-2 inhibitors were widely regarded as safer to prescribe in patients at high risk of developing gastrointestinal side effects than NSAIDs,2 although there were doubts over their cardiovascular safety.3 Working in general practice at the time, we saw COX-2 inhibitors used in primary care patients who had mild upper gastrointestinal symptoms or history, as a safe option. They were prescribed particularly in elderly people, in whom opiate analgesics often cause significant adverse effects. This practice would have led to a higher risk cohort of patients being prescribed COX-2 inhibitors rather than NSAIDs, thus reducing the apparent safety of COX-2 inhibitors in this study.
Additionally, during the study period both ulcer healing drugs and NSAIDs
Michael R Lewis, general practitioner1, Diana Kay, general practitioner2
1 Welshpool Medical Centre, Powys SY21 7ER Michael.Lewis@gp-w96010.wales.nhs.uk, 2 Cheam Family Practice, Sutton, Surrey SM1 2HD